Senesco insiders elect to convert common stock formerly held by Stanford Venture Capital at $0.83

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE SNT) reported today that the insiders of the Company who had previously purchased all of the convertible debentures, warrants and common stock of Senesco which were formerly held by Stanford Venture Capital Holdings, Inc. have elected, subject to shareholder approval, to convert the convertible debentures at a conversion price of $0.83.  Under the terms of the convertible debentures, such convertible debentures could have converted at a floating conversion rate equal to the lower of $0.83, or 80 percent of the lowest daily Volume-Weighted Average Price (VWAP) for the five-day period immediately preceding the conversion date, which equated to $0.22.

"Although insiders had the option to convert at a lower price based on the VWAP, they elected to convert at $0.83, which was the highest contractual conversion price possible," said Harlan Waksal, M.D., Senesco's Chairman of the Board.  "This both minimizes shareholder dilution and strengthens Senesco's balance sheet.  As a company, we remain committed to attracting sufficient financing and filing an IND for SNS-01, our multiple myeloma drug candidate."  

SOURCE Senesco Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.